All Oncology News

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Rohan Maniar, MD, details considerations when treating patients with rare thymic epithelial tumors as well as notable ongoing research in the field.

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

Neoadjuvant chemotherapy and concurrent chemoradiation could represent a safe, effective bladder-sparing approach in MIBC.

Some patients with metastatic kidney cancer achieving a good response to a combination therapy can safely stop or pause treatment after 2 years.

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

Amy M. Ahnert, MD, highlights newer shared risk factors for CVD and breast cancer and questions regarding personalized screening for the diseases.

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Kelly E. McCann, MD, PhD, discusses how novel ADCs and targeted therapies could improve treatment strategies in HER2-positive breast cancer.

Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

The FDA granted fast track designation to IBI363 for squamous non–small cell lung cancer.

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.

The FDA and European Commission have approved 2 biosimilars referencing denosumab for cancer-related bone loss and other indications.

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.